A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

2期 已完成 NCT03006848

摘要

This clinical trial seeks to determine if avelumab will be effective in facilitating removal of all gross tumor in the event of a relapse of osteosarcoma in pediatric patients. Avelumab will be evaluated using dosing that has previously been determined in adult studies. Primary Objectives: * To estimate the response rate to 4 cycles of avelumab in patients with recurrent or progressive osteosarcoma. * To estimate the 16-week progression free survival of patients with recurrent or progressive osteosarcoma after treatment with avelumab. Secondary Objective: * To describe the toxicities associated with the administration of avelumab in patients with recurrent or progressive osteosarcoma. * To assess the quality of life of patients with recurrent or progressive osteosarcoma undergoing treatment with avelumab, and to explore relationships between clinical factors and patient-reported health-related quality of life (HRQOL) outcomes. Exploratory Objectives: * To explore factors associated with response in patients treated with avelumab after recurrent or progressive osteosarcoma (e.g. tumor PD-L1 expression). * To measure parameters of immune activation including subsets of peripheral blo

Response Rate

At the end of 4 cycles of avelumab (approximately 4 months) · percentage of participants

Progression-free Survival

At the end of 4 cycles of avelumab (approximately 4 months) · percentage of weeks

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

全部试验